Share on StockTwits

Equities researchers at Brinson Patrick assumed coverage on shares of Stemcells (NASDAQ:STEM) in a research report issued on Wednesday. The firm set an “outperform” rating and a $7.00 price target on the stock. Brinson Patrick’s price objective indicates a potential upside of 250.00% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group raised their price target on shares of Stemcells from $2.50 to $5.00 in a research note on Friday, June 20th. They now have a “buy” rating on the stock. Separately, analysts at Chardan Capital reiterated a “positive” rating on shares of Stemcells in a research note on Tuesday, June 17th.

Stemcells (NASDAQ:STEM) opened at 2.00 on Wednesday. Stemcells has a one year low of $1.15 and a one year high of $2.34. The stock’s 50-day moving average is $1.57 and its 200-day moving average is $1.43. The company’s market cap is $111.0 million.

Stemcells (NASDAQ:STEM) last released its earnings data on Wednesday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.24 million. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Analysts expect that Stemcells will post $-0.60 EPS for the current fiscal year.

StemCells, Inc (NASDAQ:STEM) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.